MeSH term
Frequency | Condition_Probility | Catecholamines/*physiology | 5 | 31.0 |
Dopamine beta-Hydroxylase/*deficiency/genetics | 2 | 100.0 |
Humans | 467 | 0.0 |
Norepinephrine/deficiency | 2 | 100.0 |
Alleles | 20 | 0.0 |
Attention Deficit Disorder with Hyperactivity/*genetics | 2 | 4.0 |
Chromosome Mapping | 16 | 0.0 |
Dopamine beta-Hydroxylase/*genetics | 49 | 98.0 |
Gene Frequency | 18 | 0.0 |
Introns/genetics | 2 | 0.0 |
Linkage (Genetics) | 5 | 0.0 |
Nuclear Family | 3 | 1.0 |
Research Support, Non-U.S. Gov't | 173 | 0.0 |
Polymerase Chain Reaction/*methods | 2 | 0.0 |
Thailand | 2 | 1.0 |
Animals | 94 | 0.0 |
Binding Sites/physiology | 3 | 1.0 |
Cell Differentiation | 2 | 0.0 |
Dopamine beta-Hydroxylase/genetics/metabolism | 2 | 66.0 |
Mutagenesis, Site-Directed | 6 | 0.0 |
Norepinephrine/*metabolism | 8 | 23.0 |
Rats | 45 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 118 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Transfection | 14 | 0.0 |
Amino Acid Sequence | 25 | 0.0 |
Cell Line | 8 | 0.0 |
Cyclic AMP-Dependent Protein Kinases/*metabolism | 2 | 2.0 |
DNA/metabolism | 4 | 0.0 |
Dopamine beta-Hydroxylase/*genetics/metabolism | 8 | 100.0 |
Electrophoresis, Gel, Two-Dimensional | 2 | 0.0 |
Genes, Reporter | 3 | 0.0 |
Homeodomain Proteins/chemistry/*metabolism | 2 | 13.0 |
Models, Biological | 2 | 0.0 |
Molecular Sequence Data | 48 | 0.0 |
Plasmids/metabolism | 2 | 0.0 |
Promoter Regions (Genetics) | 17 | 0.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Signal Transduction | 2 | 0.0 |
Transcription, Genetic | 5 | 0.0 |
Tumor Cells, Cultured | 22 | 0.0 |
Adult | 210 | 0.0 |
Cohort Studies | 3 | 0.0 |
Depressive Disorder, Major/diagnosis/enzymology/*genetics | 2 | 100.0 |
Exons | 5 | 0.0 |
Female | 216 | 0.0 |
*Genotype | 4 | 1.0 |
Male | 255 | 0.0 |
Middle Aged | 170 | 0.0 |
Polymorphism, Genetic/*genetics | 4 | 0.0 |
Psychiatric Status Rating Scales | 13 | 6.0 |
Aged | 76 | 0.0 |
Dopamine beta-Hydroxylase/blood/*genetics | 11 | 100.0 |
Hydrocortisone/blood | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 36 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Catecholamines/biosynthesis/*genetics | 2 | 100.0 |
Comparative Study | 72 | 0.0 |
Dopamine beta-Hydroxylase/genetics | 19 | 73.0 |
Embryo | 2 | 0.0 |
Mice | 29 | 0.0 |
Mice, Transgenic | 11 | 0.0 |
*Recombination, Genetic | 2 | 0.0 |
Attention Deficit Disorder with Hyperactivity/enzymology/*genetics | 2 | 66.0 |
Family Health | 3 | 0.0 |
Genotype | 21 | 0.0 |
Polymorphism, Genetic | 9 | 0.0 |
Base Sequence | 54 | 0.0 |
DNA/chemistry/genetics | 2 | 0.0 |
DNA Mutational Analysis | 3 | 0.0 |
Dopamine/blood | 8 | 33.0 |
Epinephrine/blood | 7 | 5.0 |
Mutation | 8 | 0.0 |
Pedigree | 17 | 0.0 |
Aged, 80 and over | 8 | 0.0 |
Biogenic Monoamines/*metabolism | 2 | 20.0 |
Dopamine beta-Hydroxylase/*metabolism | 21 | 100.0 |
DNA, Neoplasm/genetics | 2 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
*Escherichia coli Proteins | 2 | 0.0 |
Kinetics | 8 | 0.0 |
Models, Molecular | 3 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Dinoprostone/*pharmacology | 2 | 3.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Binding Sites | 6 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Blotting, Western | 4 | 0.0 |
Dopamine beta-Hydroxylase/metabolism | 20 | 80.0 |
Fluorescent Antibody Technique, Indirect | 3 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Tyrosine 3-Monooxygenase/metabolism | 10 | 6.0 |
Ubiquitin Thiolesterase | 7 | 6.0 |
Vasoactive Intestinal Peptide/metabolism | 2 | 2.0 |
Exploratory Behavior/*physiology | 2 | 11.0 |
Lod Score | 6 | 0.0 |
Adolescent | 61 | 0.0 |
Child | 44 | 0.0 |
Child, Preschool | 27 | 0.0 |
Dopamine beta-Hydroxylase/*blood | 131 | 98.0 |
Infant | 20 | 0.0 |
Catecholamines/metabolism | 5 | 11.0 |
DNA Footprinting | 5 | 1.0 |
Dopamine beta-Hydroxylase/genetics/*metabolism | 3 | 100.0 |
*Gene Expression Regulation | 3 | 0.0 |
Immunohistochemistry | 28 | 0.0 |
Neurons/cytology/*enzymology | 2 | 10.0 |
Organ Specificity | 7 | 0.0 |
Promoter Regions (Genetics)/genetics | 3 | 0.0 |
Central Nervous System Depressants/pharmacology | 2 | 16.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Gene Expression Regulation/*drug effects | 2 | 0.0 |
Mice, Inbred DBA | 2 | 0.0 |
*Symporters | 3 | 3.0 |
Carrier Proteins/genetics | 4 | 1.0 |
Case-Control Studies | 7 | 0.0 |
European Continental Ancestry Group | 3 | 0.0 |
*Genetic Predisposition to Disease | 2 | 0.0 |
*Membrane Transport Proteins | 6 | 1.0 |
*Nerve Tissue Proteins | 9 | 2.0 |
*Polymorphism, Genetic | 9 | 0.0 |
Polymorphism, Restriction Fragment Length | 6 | 0.0 |
Receptors, Dopamine/genetics | 3 | 25.0 |
Reference Values | 15 | 0.0 |
DNA Primers | 10 | 0.0 |
Gene Expression Regulation, Enzymologic/*physiology | 3 | 3.0 |
Introns | 3 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Transcription, Genetic/*physiology | 3 | 1.0 |
Catechol O-Methyltransferase/genetics | 3 | 10.0 |
Dopamine/*metabolism | 7 | 6.0 |
Monoamine Oxidase/genetics | 2 | 9.0 |
In Situ Hybridization | 5 | 0.0 |
Microscopy, Electron | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Brain/*enzymology | 4 | 2.0 |
*Gene Expression Regulation, Enzymologic | 3 | 0.0 |
Levodopa/therapeutic use | 3 | 11.0 |
RNA, Messenger/genetics | 3 | 0.0 |
*Transcription, Genetic | 3 | 0.0 |
Tyrosine 3-Monooxygenase/*genetics | 8 | 6.0 |
Models, Genetic | 9 | 0.0 |
Schizophrenia/genetics | 2 | 7.0 |
*Linkage (Genetics) | 5 | 0.0 |
Receptors, Dopamine D1/genetics | 2 | 33.0 |
Receptors, Dopamine D2/*genetics | 3 | 0.0 |
Treatment Outcome | 2 | 0.0 |
*Dinucleotide Repeats | 2 | 5.0 |
*Chromosomes, Human, Pair 9 | 8 | 3.0 |
DNA, Complementary/*genetics | 2 | 0.0 |
Genetic Markers | 7 | 0.0 |
Sequence Tagged Sites | 2 | 0.0 |
Haplotypes | 4 | 0.0 |
Linkage Disequilibrium | 4 | 0.0 |
Norepinephrine/physiology | 4 | 25.0 |
Bipolar Disorder/*genetics | 4 | 3.0 |
Brain/enzymology | 6 | 3.0 |
*Membrane Glycoproteins | 8 | 0.0 |
Receptors, Dopamine D2/genetics | 3 | 6.0 |
*Molecular Biology | 2 | 5.0 |
Heterozygote | 4 | 0.0 |
*Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Schizophrenia/*genetics | 3 | 1.0 |
Catecholamines/*metabolism | 11 | 21.0 |
Gene Expression | 4 | 0.0 |
Nerve Tissue Proteins/genetics | 2 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Sequence Analysis, DNA | 3 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
*Transcription Factors | 2 | 0.0 |
Norepinephrine/metabolism | 7 | 14.0 |
Regression Analysis | 4 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Odds Ratio | 3 | 0.0 |
Receptors, Dopamine D1/*genetics | 2 | 7.0 |
Risk | 2 | 0.0 |
Dopamine beta-Hydroxylase/*antagonists & inhibitors | 5 | 100.0 |
In Vitro | 5 | 0.0 |
Sympathetic Nervous System/*drug effects | 4 | 26.0 |
Dopamine beta-Hydroxylase/*analysis | 7 | 100.0 |
Immunoenzyme Techniques | 7 | 0.0 |
Analysis of Variance | 6 | 0.0 |
Longitudinal Studies | 6 | 0.0 |
DNA, Viral/analysis | 3 | 0.0 |
Japan | 2 | 0.0 |
Polymerase Chain Reaction | 16 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Neurons/*physiology | 4 | 2.0 |
Norepinephrine/*physiology | 6 | 40.0 |
Cloning, Molecular | 9 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
DNA-Binding Proteins/genetics/metabolism | 2 | 0.0 |
Genetic Complementation Test | 2 | 0.0 |
Glioma | 2 | 2.0 |
Hela Cells | 5 | 0.0 |
Neuroblastoma | 5 | 2.0 |
Nuclear Proteins/genetics/metabolism | 2 | 1.0 |
Plasmids | 2 | 0.0 |
Protein Binding/genetics | 2 | 0.0 |
Cells, Cultured | 5 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Gene Expression Regulation | 4 | 0.0 |
Genes, Regulator/*genetics | 2 | 4.0 |
Macaca mulatta | 2 | 0.0 |
Tyrosine 3-Monooxygenase/genetics | 5 | 10.0 |
Cattle | 12 | 0.0 |
Cell Count | 3 | 0.0 |
Dopamine beta-Hydroxylase/analysis | 13 | 59.0 |
Phenylethanolamine N-Methyltransferase/analysis | 2 | 33.0 |
Diagnosis, Differential | 3 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
DNA-Binding Proteins/metabolism | 2 | 0.0 |
Tetradecanoylphorbol Acetate/*pharmacology | 2 | 0.0 |
Transcription, Genetic/*drug effects | 3 | 0.0 |
Calcitonin Gene-Related Peptide/analysis | 7 | 10.0 |
Galanin/analysis | 2 | 20.0 |
Infant, Newborn | 14 | 0.0 |
Neuropeptide Y/analysis | 10 | 14.0 |
Neuropeptides/*analysis | 5 | 6.0 |
Somatostatin/analysis | 2 | 3.0 |
Substance P/analysis | 7 | 7.0 |
Tyrosine 3-Monooxygenase/analysis | 9 | 10.0 |
Vasoactive Intestinal Peptide/analysis | 8 | 8.0 |
Dopamine beta-Hydroxylase/blood | 35 | 92.0 |
Norepinephrine/blood | 15 | 7.0 |
Sympathetic Nervous System/*physiopathology | 12 | 32.0 |
Aging/metabolism | 2 | 1.0 |
Catecholamines/*biosynthesis | 7 | 43.0 |
Phenotype | 7 | 0.0 |
Tyrosine 3-Monooxygenase/*metabolism | 8 | 9.0 |
*Genes, Structural | 4 | 0.0 |
*Linkage Disequilibrium | 3 | 1.0 |
Dopamine beta-Hydroxylase/*deficiency | 3 | 100.0 |
English Abstract | 34 | 0.0 |
Nucleic Acid Hybridization | 5 | 0.0 |
Polymerase Chain Reaction/methods | 3 | 0.0 |
Homozygote | 2 | 0.0 |
Adrenal Medulla/metabolism | 3 | 21.0 |
Genetic Code | 2 | 4.0 |
Phenylethanolamine N-Methyltransferase/genetics | 2 | 33.0 |
Cyclic AMP/*metabolism | 3 | 1.0 |
Point Mutation | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
Recombinant Fusion Proteins/biosynthesis | 2 | 0.0 |
Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Dopamine beta-Hydroxylase/*biosynthesis/genetics | 3 | 100.0 |
PC12 Cells | 4 | 1.0 |
Neurons/*enzymology | 3 | 4.0 |
Rabbits | 2 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
Disease Susceptibility | 2 | 0.0 |
Brain/*metabolism | 3 | 0.0 |
Serotonin/*metabolism | 3 | 6.0 |
Gene Frequency/genetics | 2 | 0.0 |
Choline O-Acetyltransferase/analysis | 2 | 4.0 |
Norepinephrine/analysis | 4 | 23.0 |
Staining and Labeling | 3 | 0.0 |
*Variation (Genetics) | 4 | 0.0 |
Biological Markers/blood | 3 | 0.0 |
Cross-Sectional Studies | 2 | 0.0 |
Monoamine Oxidase/blood | 8 | 72.0 |
Prolactin/blood | 8 | 1.0 |
Dopamine beta-Hydroxylase/*drug effects | 2 | 100.0 |
Monoamine Oxidase/*drug effects | 2 | 100.0 |
Dose-Response Relationship, Drug | 4 | 0.0 |
Sex Factors | 14 | 0.0 |
*Genes | 2 | 0.0 |
*Genes, Regulator | 3 | 2.0 |
Oligonucleotide Probes/genetics | 4 | 3.0 |
*Promoter Regions (Genetics) | 8 | 0.0 |
Stereoisomerism | 2 | 0.0 |
Autistic Disorder/*genetics | 2 | 3.0 |
Intelligence Tests | 2 | 3.0 |
Monoamine Oxidase/*genetics | 2 | 2.0 |
Catecholamines/blood/*metabolism | 2 | 50.0 |
Random Allocation | 2 | 0.0 |
*Environmental Monitoring | 2 | 6.0 |
Carbon Disulfide/*adverse effects | 2 | 50.0 |
Occupational Exposure/*adverse effects | 3 | 3.0 |
Norepinephrine/pharmacology | 3 | 3.0 |
Dopamine/*physiology | 2 | 2.0 |
Pregnancy | 8 | 0.0 |
Electrocardiography | 4 | 1.0 |
Prospective Studies | 4 | 0.0 |
Time Factors | 20 | 0.0 |
Cell Line, Transformed | 2 | 0.0 |
Glycosylation | 2 | 0.0 |
Neurons/*metabolism | 3 | 1.0 |
Sequence Homology, Nucleic Acid | 4 | 0.0 |
Monoamine Oxidase/*blood | 18 | 58.0 |
Substance Withdrawal Syndrome/enzymology | 2 | 66.0 |
Thiolester Hydrolases/analysis | 4 | 11.0 |
Histocytochemistry | 8 | 1.0 |
Homovanillic Acid/*blood | 3 | 37.0 |
Personality Development | 2 | 50.0 |
Risk Factors | 4 | 0.0 |
DNA/analysis | 2 | 0.0 |
*Mutation | 2 | 0.0 |
Aggression/physiology | 2 | 25.0 |
Follow-Up Studies | 5 | 0.0 |
Adrenal Gland Neoplasms/*enzymology | 4 | 57.0 |
Pheochromocytoma/*enzymology | 4 | 57.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Dopamine beta-Hydroxylase/blood/*drug effects | 2 | 100.0 |
Catecholamines/biosynthesis | 2 | 15.0 |
Neuropeptides/*metabolism | 2 | 2.0 |
Blood Platelets/enzymology | 13 | 29.0 |
Chronic Disease | 7 | 0.0 |
Dopamine beta-Hydroxylase/deficiency | 3 | 100.0 |
Heart Rate | 9 | 3.0 |
Posture | 11 | 11.0 |
Cats | 6 | 1.0 |
Dogs | 5 | 0.0 |
Guinea Pigs | 8 | 0.0 |
Species Specificity | 7 | 0.0 |
Swine | 5 | 0.0 |
Temperature | 2 | 0.0 |
Immunoblotting | 3 | 0.0 |
Bladder/chemistry/*innervation | 2 | 100.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Neural Pathways | 2 | 11.0 |
Neurons/physiology | 2 | 1.0 |
Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Arousal/physiology | 4 | 18.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Tuberous Sclerosis/*genetics | 3 | 3.0 |
DNA, Viral/*analysis | 2 | 2.0 |
Restriction Mapping | 3 | 0.0 |
Adrenal Glands/enzymology | 3 | 16.0 |
Cyclic AMP/metabolism | 2 | 0.0 |
RNA/analysis | 2 | 0.0 |
Fluorescent Antibody Technique | 7 | 0.0 |
Autonomic Nervous System/physiopathology | 3 | 11.0 |
Hemodynamic Processes | 5 | 2.0 |
Tyrosine 3-Monooxygenase/antagonists & inhibitors | 2 | 40.0 |
Blood Pressure | 23 | 3.0 |
Epinephrine/*urine | 2 | 66.0 |
Norepinephrine/urine | 7 | 53.0 |
Vanilmandelic Acid/*urine | 2 | 66.0 |
Dopamine beta-Hydroxylase/immunology | 2 | 100.0 |
Dopamine beta-Hydroxylase/blood/*metabolism | 5 | 100.0 |
Parents | 2 | 2.0 |
Oligodeoxyribonucleotides | 4 | 0.0 |
Poly A/genetics/isolation & purification | 2 | 5.0 |
RNA/genetics/isolation & purification | 2 | 1.0 |
RNA, Messenger | 2 | 0.0 |
Macromolecular Substances | 2 | 0.0 |
Sympathetic Nervous System/*physiology | 5 | 10.0 |
Haplorhini | 2 | 0.0 |
*Cardiac Surgical Procedures | 2 | 4.0 |
Postoperative Period | 2 | 0.0 |
Antipsychotic Agents/therapeutic use | 4 | 13.0 |
Norepinephrine/*blood | 13 | 22.0 |
*Schizophrenic Psychology | 3 | 4.0 |
Blotting, Northern | 4 | 0.0 |
Protein Processing, Post-Translational | 2 | 0.0 |
Phenylethanolamine N-Methyltransferase/metabolism | 4 | 28.0 |
Rats, Inbred Strains | 5 | 0.0 |
Sympathetic Nervous System/physiology | 8 | 29.0 |
Acute Disease | 10 | 0.0 |
Chromatography, High Pressure Liquid | 4 | 0.0 |
Dopamine beta-Hydroxylase/*cerebrospinal fluid | 6 | 100.0 |
Catecholamines/blood | 3 | 6.0 |
Dopamine/urine | 3 | 75.0 |
DNA/genetics | 2 | 0.0 |
Blood Pressure/*drug effects | 3 | 1.0 |
Genes, Structural | 2 | 0.0 |
Phenylethanolamine N-Methyltransferase/*analysis | 3 | 42.0 |
Tyrosine 3-Monooxygenase/*analysis | 3 | 8.0 |
Locus Coeruleus/*enzymology/pathology | 2 | 100.0 |
Dopamine/analysis | 2 | 13.0 |
Blood Platelets/*enzymology | 5 | 6.0 |
Epinephrine/biosynthesis | 2 | 50.0 |
Phenylethanolamine N-Methyltransferase/*genetics | 2 | 11.0 |
Adrenal Gland Neoplasms/enzymology | 2 | 40.0 |
Centrifugation, Density Gradient | 2 | 0.0 |
Chromaffin Granules/enzymology | 3 | 100.0 |
Pheochromocytoma/enzymology | 2 | 28.0 |
Autonomic Nervous System/*physiopathology | 3 | 15.0 |
Sweden | 3 | 1.0 |
Dopamine/metabolism | 4 | 3.0 |
Chromosomes, Human, Pair 9 | 2 | 1.0 |
Colchicine/therapeutic use | 2 | 18.0 |
Brain Chemistry | 3 | 1.0 |
Cross Reactions | 2 | 0.0 |
Dopamine beta-Hydroxylase/*analysis/immunology | 2 | 100.0 |
Enzyme-Linked Immunosorbent Assay | 3 | 0.0 |
Immunodiffusion | 2 | 0.0 |
Dopamine beta-Hydroxylase/*blood/genetics | 7 | 100.0 |
Heat | 2 | 0.0 |
Cerebrospinal Fluid Proteins/analysis | 2 | 8.0 |
Jews | 2 | 2.0 |
Adrenal Medulla/*enzymology | 3 | 50.0 |
Depressive Disorder/drug therapy/*enzymology | 3 | 100.0 |
Dopamine beta-Hydroxylase/*blood/deficiency | 2 | 100.0 |
Age Factors | 15 | 0.0 |
Catecholamines/*analysis | 2 | 25.0 |
Diuresis | 2 | 6.0 |
Epinephrine/urine | 4 | 57.0 |
Arousal/*physiology | 2 | 6.0 |
Catecholamines/*urine | 2 | 33.0 |
Homovanillic Acid/urine | 2 | 20.0 |
Vanilmandelic Acid/urine | 2 | 20.0 |
Dopamine/*blood | 2 | 28.0 |
Homovanillic Acid/cerebrospinal fluid | 5 | 33.0 |
Schizophrenia/*physiopathology | 2 | 13.0 |
Blood Pressure/drug effects | 9 | 1.0 |
Heart Rate/drug effects | 3 | 1.0 |
Catecholamines/*blood | 6 | 18.0 |
Catechol O-Methyltransferase/*blood | 7 | 25.0 |
Psychological Tests | 3 | 7.0 |
Syndrome | 2 | 0.0 |
Body Weight | 3 | 0.0 |
Catecholamines/*metabolism/urine | 2 | 100.0 |
Thyrotropin/blood | 4 | 1.0 |
Renal Dialysis | 3 | 0.0 |
ABO Blood-Group System/genetics | 2 | 4.0 |
*Chromosome Mapping | 2 | 0.0 |
Cell Membrane/enzymology | 2 | 0.0 |
Cytosol/enzymology | 2 | 1.0 |
Radioimmunoassay | 3 | 0.0 |
Vasoconstriction/*drug effects | 2 | 5.0 |
Methods | 3 | 1.0 |
Genes, Dominant | 2 | 0.0 |
Dementia/enzymology | 2 | 33.0 |
Depressive Disorder/*enzymology/psychology | 4 | 100.0 |
Epinephrine/metabolism | 3 | 20.0 |
Clinical Trials | 2 | 0.0 |
Double-Blind Method | 2 | 0.0 |
Cerebral Ventricles/pathology | 2 | 13.0 |
Homovanillic Acid/*urine | 2 | 40.0 |
*Renal Dialysis | 6 | 1.0 |
Serotonin/*blood | 2 | 14.0 |
Thyroxine/blood | 5 | 1.0 |
Triiodothyronine/blood | 2 | 0.0 |
Exertion | 7 | 10.0 |
*Electroencephalography | 2 | 1.0 |
Schizophrenic Psychology | 2 | 5.0 |
Social Adjustment | 2 | 20.0 |
Brain/*physiology | 2 | 1.0 |
Dopamine/physiology | 2 | 3.0 |
Personality | 2 | 11.0 |
Synaptic Transmission | 2 | 5.0 |
Dopamine beta-Hydroxylase/blood/cerebrospinal fluid | 2 | 100.0 |
Hydroxyindoleacetic Acid/cerebrospinal fluid | 3 | 21.0 |
*Twins | 2 | 7.0 |
*Twins, Monozygotic | 2 | 11.0 |
Epinephrine/*blood | 5 | 17.0 |
*Exertion | 4 | 2.0 |
Isometric Contraction | 2 | 11.0 |
Hippocampus/anatomy & histology | 2 | 100.0 |
Molecular Weight | 4 | 0.0 |
Dopamine beta-Hydroxylase/analysis/*metabolism | 2 | 100.0 |
Erythrocytes/enzymology | 6 | 1.0 |
Gene Deletion | 2 | 0.0 |
Schizophrenia/*drug therapy/enzymology | 2 | 66.0 |
Renin/*blood | 11 | 11.0 |
Depression/enzymology | 3 | 75.0 |
Dopamine beta-Hydroxylase/*analysis/blood/cerebrospinal fluid | 2 | 100.0 |
Monoamine Oxidase/*metabolism | 2 | 8.0 |
Schizophrenia/*enzymology | 4 | 36.0 |
Endorphins/*metabolism | 2 | 33.0 |
Acetic Acid | 2 | 11.0 |
Acetic Acids/*therapeutic use | 2 | 66.0 |
Bicarbonates/*therapeutic use | 2 | 50.0 |
Kidney Diseases/*blood/therapy | 2 | 50.0 |
Kininogens/*blood | 2 | 66.0 |
Choline O-Acetyltransferase/metabolism | 3 | 2.0 |
Dopa Decarboxylase/metabolism | 3 | 60.0 |
Catechol O-Methyltransferase/metabolism | 2 | 16.0 |
Prognosis | 4 | 0.0 |
African Continental Ancestry Group | 2 | 0.0 |
Hypertension/*enzymology | 5 | 50.0 |
*Blood Pressure | 6 | 4.0 |
Lipids/*blood | 2 | 0.0 |
Diet | 3 | 0.0 |
Dopamine beta-Hydroxylase/*cerebrospinal fluid/metabolism | 2 | 100.0 |
Exercise Test | 2 | 0.0 |
Propranolol/*pharmacology | 2 | 12.0 |
Erythrocytes/*enzymology | 2 | 0.0 |
Bipolar Disorder/enzymology/psychology | 2 | 100.0 |
Aging | 4 | 1.0 |
Catecholamines/urine | 4 | 33.0 |
Clonidine/*pharmacology | 2 | 8.0 |
Hypertension/blood/*physiopathology | 2 | 10.0 |
Enzyme Tests | 2 | 2.0 |
Affective Disorders, Psychotic/*enzymology | 2 | 100.0 |
Bipolar Disorder/enzymology | 6 | 75.0 |
Depressive Disorder/enzymology | 2 | 66.0 |
Sleep/drug effects | 2 | 16.0 |
Phenethylamines/metabolism | 2 | 33.0 |
Schizophrenia/enzymology | 3 | 42.0 |
Pulse/drug effects | 3 | 15.0 |
Renin/blood | 8 | 2.0 |
Adrenal Glands/*enzymology | 2 | 15.0 |
Phenylethanolamine N-Methyltransferase/*metabolism | 4 | 28.0 |
Catechol O-Methyltransferase/*genetics | 2 | 2.0 |
Genes, Recessive | 2 | 0.0 |
Israel | 2 | 1.0 |
Bipolar Disorder/*enzymology/psychology | 2 | 100.0 |
Haloperidol/therapeutic use | 2 | 22.0 |
Schizophrenia/drug therapy/*enzymology | 2 | 66.0 |
Myocardium/enzymology/*metabolism | 2 | 14.0 |
Adrenal Medulla/enzymology | 3 | 42.0 |
Copper/pharmacology | 3 | 5.0 |
Parkinson Disease/enzymology | 2 | 25.0 |
Blood Proteins/analysis | 2 | 1.0 |
Cyclic AMP/blood | 3 | 8.0 |
Respiration | 2 | 3.0 |
Menstruation | 2 | 3.0 |
*Renin-Angiotensin System | 2 | 7.0 |
Schizophrenia/*enzymology/genetics | 4 | 50.0 |
Metoclopramide/*diagnostic use | 2 | 11.0 |
Norepinephrine/biosynthesis | 2 | 66.0 |
Aldosterone/blood | 2 | 1.0 |
Diet, Sodium-Restricted | 3 | 10.0 |
Sodium/urine | 2 | 3.0 |
Aldosterone/*blood | 3 | 6.0 |
Dopamine/biosynthesis | 2 | 20.0 |
Schizophrenia, Paranoid/enzymology | 2 | 50.0 |
*Menstruation | 3 | 7.0 |
Ovulation | 3 | 5.0 |
Dopamine beta-Hydroxylase/antagonists & inhibitors/*blood | 4 | 100.0 |
Mental Disorders/*enzymology | 2 | 100.0 |
Membrane Transport Proteins/genetics | 2 | 6.0 |
*MMPI | 2 | 50.0 |
Diseases in Twins | 3 | 6.0 |
Hematocrit | 3 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Dopa Decarboxylase/*metabolism | 2 | 25.0 |
Circadian Rhythm | 4 | 1.0 |
Placebos | 2 | 0.0 |
Hypertension/*physiopathology | 3 | 4.0 |
Disulfiram/*adverse effects/therapeutic use | 2 | 66.0 |
*Circadian Rhythm | 2 | 0.0 |
Cold | 3 | 2.0 |
Stress | 2 | 3.0 |
Alcoholism/*enzymology | 2 | 14.0 |
Insulin/diagnostic use | 2 | 4.0 |
Psychotic Disorders/*enzymology | 2 | 66.0 |
Estradiol/blood | 2 | 0.0 |
Progesterone/blood | 2 | 0.0 |
Sympathetic Nervous System/physiopathology | 5 | 20.0 |
Membrane Transport Proteins/*genetics | 2 | 3.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Hypertension/metabolism/*physiopathology | 2 | 33.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Alcoholism/*drug therapy | 2 | 50.0 |
Heart Failure, Congestive/enzymology | 2 | 50.0 |
Hypertension/*blood/enzymology | 2 | 33.0 |
Stimulation, Chemical | 2 | 0.0 |
Blood Glucose/*metabolism | 2 | 0.0 |
Stress, Psychological | 3 | 10.0 |
Genetics, Population | 2 | 0.0 |
Minnesota | 2 | 9.0 |
Stress, Psychological/physiology | 2 | 100.0 |
Acetylcholine/metabolism | 2 | 6.0 |
Coronary Disease/enzymology | 2 | 40.0 |
Hypertension/enzymology | 3 | 30.0 |
Blood Volume | 2 | 4.0 |
Contraceptives, Oral/*adverse effects | 2 | 9.0 |
Peripheral Nerves/physiology | 2 | 33.0 |
